Exelixis Inc (EXEL)

May 23, 2025, 6:25 AM EDT - 11 days ago

Product Performance, Big Money Lift Exelixis

May 22, 2025, 5:17 PM EDT - 12 days ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

May 22, 2025, 4:05 PM EDT - 12 days ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

May 14, 2025, 2:53 PM EDT - 20 days ago

Exelixis: A Notable Quarter

May 14, 2025, 10:44 AM EDT - 20 days ago

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

May 13, 2025, 8:31 PM EDT - 21 days ago

Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript

May 13, 2025, 6:06 PM EDT - 21 days ago

Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

May 13, 2025, 4:07 PM EDT - 21 days ago

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 4:05 PM EDT - 27 days ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

Apr 29, 2025, 4:05 PM EDT - 5 weeks ago

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Apr 29, 2025, 2:02 AM EDT - 5 weeks ago

EXEL Industries: Second quarter 2024–2025 sales down 3.8%

Mar 26, 2025, 9:15 AM EDT - 2 months ago

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Mar 25, 2025, 5:15 PM EDT - 2 months ago

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

Mar 19, 2025, 7:09 AM EDT - 2 months ago

Exelixis Growth Continues with Big Money Boosts

Feb 25, 2025, 4:05 PM EST - 3 months ago

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

Feb 21, 2025, 1:30 PM EST - 3 months ago

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Feb 20, 2025, 5:05 PM EST - 3 months ago

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

Feb 15, 2025, 11:10 AM EST - 3 months ago

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

Feb 13, 2025, 4:05 PM EST - 3 months ago

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

Feb 12, 2025, 9:04 AM EST - 3 months ago

Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow

Feb 11, 2025, 8:24 PM EST - 4 months ago

Exelixis, Inc. (EXEL) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 4:05 PM EST - 4 months ago

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

Jan 28, 2025, 4:05 PM EST - 4 months ago

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Jan 25, 2025, 10:00 AM EST - 4 months ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025

Jan 24, 2025, 2:30 PM EST - 4 months ago

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

Jan 22, 2025, 7:44 AM EST - 4 months ago

Revenues, Treatment Pipeline Driving Exelixis Higher

Jan 12, 2025, 4:00 PM EST - 5 months ago

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

Jan 10, 2025, 5:29 PM EST - 5 months ago

The Best Defensive Stocks To Hedge Against Market Uncertainty

EXC PM PPC RTX

Jan 9, 2025, 4:19 PM EST - 5 months ago

Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza

Jan 9, 2025, 9:00 AM EST - 5 months ago

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Jan 6, 2025, 4:05 PM EST - 5 months ago

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Nov 27, 2024, 4:05 PM EST - 6 months ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

Nov 26, 2024, 4:05 PM EST - 6 months ago

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Nov 7, 2024, 4:05 PM EST - 7 months ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Oct 31, 2024, 9:55 AM EDT - 7 months ago

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Oct 29, 2024, 10:31 PM EDT - 7 months ago

Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 4:05 PM EDT - 7 months ago

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 21, 2024, 4:17 PM EDT - 8 months ago

3 Attractive Biotechs With Recent Positives

FOLD MRK TEVA XBI

Oct 18, 2024, 4:41 AM EDT - 8 months ago

Exelixis Stays Strong With Cabometyx While New Assets Approach Key Trials

Oct 15, 2024, 4:05 PM EDT - 8 months ago

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Oct 15, 2024, 1:57 PM EDT - 8 months ago

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

Oct 14, 2024, 8:00 AM EDT - 8 months ago

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma

MRK

Sep 16, 2024, 8:45 AM EDT - 9 months ago

Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Sep 15, 2024, 8:45 AM EDT - 9 months ago

Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024

Aug 28, 2024, 4:05 PM EDT - 9 months ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September

Aug 16, 2024, 8:09 AM EDT - 10 months ago

Exelixis Earnings Drive Share Growth

Aug 13, 2024, 12:45 PM EDT - 10 months ago

4 Best Defensive Stocks For A Potential Soft Landing (SA Quant)

PPC SO TSN

Aug 8, 2024, 4:04 PM EDT - 10 months ago

Exelixis: sNDA Cabometyx Expansion Could Provide Revenue Boost

Aug 7, 2024, 2:58 PM EDT - 10 months ago

Argonne's Autonomie Express tool simulates real-world vehicle traffic to predict large-scale energy impact

ULS

Aug 7, 2024, 2:29 PM EDT - 10 months ago

Invenra Highlights Exelixis' Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors